Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™)

About this update from Atrium Therapeutics, Inc.

[{"type":"text","content":"Participant dosed with AOC 1001 in the Phase 1/2 MARINA™ trial in adults with myotonic dystrophy type 1 (DM1)\n\n\nLA JOLLA, Calif., Nov. 4, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the first participants in the Phase 1/2 MARINA trial have been dosed with Avidity's lead AOC product candidate, AOC 1001, marking the first time a person has been dosed with an AOC. \n\n \n \n\n \n\"This is a first for this new class of drugs and it is a significant milestone for the DM1 community, the Avidity team and the RNA field,\" said Sarah Boyce, president and CEO of Avidity. \"AOCs have the potential to expand the possibilities of how we can treat diseases and our goal is to deliver meaningful drugs to patients as quickly as possible. AOC 1001's MARINA trial will offer a first glimpse of proof-of-concept data for the AOC platform to better inform the development path for DM1 as well as future treatments for other diseases with limited therapeutic options.\"\nAOCs are designed to combine the proven technology of monoclonal antibodies with the precision and potency of oligonucleotide therapies to access previously untreatable tissue and cell types. AOC 1001 consists of a proprietary monoclonal antibody that binds to the transferrin receptor 1 (TfR1) conjugated with a small interfering RNA (siRNA). It is designed to address the root cause of DM1 by targeting DMPK, the disease-related mRNA. \nTanya Stevenson, EdD, MPH, CEO of the Myotonic Dystrophy Foundation in the U.S. stated, \"This milestone represents years of research to advance treatment for DM1. Opportunities for the myotonic dystrophy community to participate in research, like the MARINA trial, are critical because the knowledge gained may help lead to earlier diagnosis, improved quality of life and, ultimately, a treatment. The MARINA trial offers much needed advancement in the treatment of DM1 and may also advance therapies for other repeat expansion diseases. We are more hopeful, encouraged and excited than ever before.\"\n\"The AOC platform was developed entirely in-house at Avidity. Our team has created this new technology through years of engineering and following the data to optimize each component of our ...

More updates from Atrium Therapeutics, Inc.